TY - JOUR
T1 - Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo
AU - Biermann, Jürgen
AU - Wu, Kezhong
AU - Odening, Katja E.
AU - Asbach, Stefan
AU - Koren, Gideon
AU - Peng, Xuwen
AU - Zehender, Manfred
AU - Bode, Christoph
AU - Brunner, Michael
N1 - Funding Information:
This work was supported by the Max-Schaldach-Forschungsstipendium of the German Cardiac Society . We thank Willi Kaiser (GE Healthcare Information Technologies, Freiburg, Germany) for supporting the analyses of μV-TWA and QT intervals.
PY - 2011/1/10
Y1 - 2011/1/10
N2 - Transgenic rabbits expressing loss-of-function pore mutants of the human gene KCNQ1 (KvLQT1-Y315S) have a Long QT-Syndrome 1 (LQT1) phenotype. We evaluated for the first time the effect of nicorandil, an opener of ATP-sensitive potassium channels, and of isoproterenol on cardiac action potential duration and heart rate dependent dispersion of repolarisation in transgenic LQT1 rabbits. In vivo LQT1 and littermate control were subjected to transvenous electrophysiological studies; in vitro monophasic action potentials were recorded from explanted Langendorff-perfused hearts. In vivo ventricular effective refractory periods (VERP) at the right ventricular base were significantly prolonged in LQT1 as compared to littermate control, resulting in a more pronounced VERP dispersion in LQT1. This difference in VERP dispersion between LQT1 and littermate control disappeared after infusion of nicorandil. In vitro, mean action potential durations (APD75 and APD90) of LQT1 were significantly prolonged compared to littermate control at baseline. Nicorandil decreased APD75 and APD90 in LQT1 and littermate control at all stimulated heart rates. After adding nicorandil, the APD90 at all hearts rates and the APD75 at high heart rates were no longer different. Dispersion of repolarisation (ΔAPD 75 and ΔAPD90) was heart rate dependently decreased after nicorandil at all tested stimulation cycle lengths only in LQT1. We demonstrated phenotypic differences of LQT1 and littermate control in vivo and in vitro. Nicorandil 20 μmol/l improved repolarisation abnormalities and heterogeneities in transgenic LQT1 rabbits.
AB - Transgenic rabbits expressing loss-of-function pore mutants of the human gene KCNQ1 (KvLQT1-Y315S) have a Long QT-Syndrome 1 (LQT1) phenotype. We evaluated for the first time the effect of nicorandil, an opener of ATP-sensitive potassium channels, and of isoproterenol on cardiac action potential duration and heart rate dependent dispersion of repolarisation in transgenic LQT1 rabbits. In vivo LQT1 and littermate control were subjected to transvenous electrophysiological studies; in vitro monophasic action potentials were recorded from explanted Langendorff-perfused hearts. In vivo ventricular effective refractory periods (VERP) at the right ventricular base were significantly prolonged in LQT1 as compared to littermate control, resulting in a more pronounced VERP dispersion in LQT1. This difference in VERP dispersion between LQT1 and littermate control disappeared after infusion of nicorandil. In vitro, mean action potential durations (APD75 and APD90) of LQT1 were significantly prolonged compared to littermate control at baseline. Nicorandil decreased APD75 and APD90 in LQT1 and littermate control at all stimulated heart rates. After adding nicorandil, the APD90 at all hearts rates and the APD75 at high heart rates were no longer different. Dispersion of repolarisation (ΔAPD 75 and ΔAPD90) was heart rate dependently decreased after nicorandil at all tested stimulation cycle lengths only in LQT1. We demonstrated phenotypic differences of LQT1 and littermate control in vivo and in vitro. Nicorandil 20 μmol/l improved repolarisation abnormalities and heterogeneities in transgenic LQT1 rabbits.
KW - Dispersion of repolarisation
KW - Electrophysiological studies
KW - Long QT-Syndrome
KW - Nicorandil
KW - Polymorphic ventricular tachycardia
KW - Transgenic rabbit model
UR - http://www.scopus.com/inward/record.url?scp=78649723140&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2010.10.016
DO - 10.1016/j.ejphar.2010.10.016
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20959120
AN - SCOPUS:78649723140
SN - 0014-2999
VL - 650
SP - 309
EP - 316
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -